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Abstract
Background: There is a growing body of literature on the relationship of Hepatitis C virus infection (HCV) and type
2 diabetes mellitus (T2DM). However, there are certain gaps in literature and the data is inconclusive. This study
was, therefore, carried out to determine the prevalence of HCV infection in diabetic patients and to elucidate the
presence of any possible relationship between HCV and T2DM in this region.
Methods: Serologic testing for anti-HCV antibody was done on a sample of 3000 individuals with T2DM visiting
Diabetes Clinic of Nishtar Medical College Hospital, Multan and 10,000 volunteer blood donors visiting blood bank
of the same hospital during the study period using Accurate rapid immunochromatographic kits which was later
confirmed by using Chemelex S.A third generation ELISA kit for positive cases. Data about various variables was
collected from diabetic patients using a structured questionnaire after taking informed consent.
Results: Prevalence rate of 13.7% for HCV infection was recorded among subjects having T2DM with seropositivity
rate of 4.9% among the control group of volunteer blood donors without diabetes. The patients with T2DM were
more likely to have HCV infection as compared to the control group (OR = 3.03, 95%CI = 2.64-3.48, p = 0.001).
Diabetic patients with age above 55 years had higher prevalence rate as compared to younger individuals. Male
patients had significantly high seropositivity as compared to female patients (15.3% vs. 12.4%, p = 0.02). Those with
duration of diabetes 11 years and above and the ones with good glycemic control had higher seroprevalence
rates of 18.2% and 18.7% respectively. There was no statistically significant difference among subjects when the
distribution of HCV was studied on the basis of marital status, locality, or family history of diabetes.
Conclusions: The results show that there is a strong association between HCV and T2DM in the region as evident
from significantly higher prevalence of HCV infection in diabetics as compared to the control group in the present
study.
Background
Hepatitis C virus (HCV) infection is an important public
health problem which currently affects more than 170
million people (about 3% of world population) out of
which 55-80% have chronic infection [1]. It is a com-
mon cause of acute and chronic hepatitis accounting for
about half of all the cases of CLD in USA [2]. The likeli-
hood of chronicity after acute HCV infection is as high
as 85% with chronic infection being common even in
those having normal aminotransferase levels after the
acute episode [3]. The progression to cirrhosis is up to
50% even in well compensated patients. The incidence
of HCC in patients with cirrhosis ranges from 1-4%,
most cases comprising of patients with HCV infection
duration exceeding 30 years [3]. The severity and rate of
progression depend on several disease related factors
and various host related factors [3,4]. Infection with
HCV has been shown to produce both hepatic and
extrahepatic manifestations, the latter including insulin
resistance, essential mixed cryoglobulinemia, glomerulo-
nephritis, porphyria cutaneous tarda and benign mono-
clonal gammopathy [5,6]. A meta-analysis showed that
HCV increases the risk of type 2 diabetes mellitus
(T2DM) by 1.8 times in excess of that posed by relative
degree of liver pathology [7].
The link between the HCV and diabetes was first
reported by Allison et al. in 1994 and later explored by
Simo and colleagues in 1996 [8,9]. The initial idea that
patients with T2DM have more parenteral exposures
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increased risk of contacting blood borne infections such
as HCV was disproved by a study from France in 1998
[10]. The epidemiological link between T2DM and HCV
has been investigated from two perspectives. Various
studies have shown high HCV seropositivity among
patients with T2DM as compared to the control group,
prevalence being two to seven times higher in the dia-
betic group [11-14]. However, other investagators per-
forming did not find such an association of HCV with
T2DM [15-17]. In addition, several studies have shown
that HCV increases the risk of development of T2DM
[7]. The mechanism of pathogenesis of diabetes in
patients with HCV infection remains unclear though it
has been implicated that insulin resistance plays an
important role and is related to fibrosis score [18-20].
After controlling for potential confounders, Mehta et al.
reported that HCV infected individuals were 3.77 times
more likely (95%CI = 1.80-.87) to have T2DM as com-
pared to those without the infection [21].
Pakistan is in the intermediate HCV prevalence area
with approximately 10 million people infected predomi-
nately with genotype 3 based on an average prevalence
rate of 6%. The prevalence ranges from 3-4% in volun-
teer blood donors according to a meta analysis. About
60-70% of the patients with CLD and half of the ones
with HCC in the country have HCV infection [22]. Dia-
betes has become an important public health problem
in Pakistan with 7.1 million diabetics in 2010 expected
to rise to 13.8 million in 2030 when the country will
rank fourth in terms of number of patients aged 20-79
with diabetes [23]
Although there is a growing body of literature on the
link between T2DM and HCV, the studies are contra-
dictory and the data is inconclusive [11,13-17,24-30].
Secondly, it is not known if diabetes is a risk factor for
the development of HCV. The study will be valuable in
this regard. Moreover, there is paucity of studies on the
subject from Pakistan with no study being from this
region to the best of our knowledge [12,31]. In addition,
the previous studies from Pakistan employed a small
sample size with no control group [12,31]. The present
study will thus be important in elucidating any relation-
s h i pb e t w e e nH C Va n dT 2 D Mi nt h er e g i o n .I na d d i -
tion, it is necessary to determine the prevalence of HCV
among diabetics to increase awareness among general
population and health care workers to prevent morbidity
and increased costs associated with this infection in dia-
betes due to failure of treatment [24]. Since the preva-
lence of diabetes is on the rise and is complicated by
coinfection with HCV, the determination of relationship
becomes even more important in this scenario so that it
can be effectively managed [23,24]. Furthermore, the
study is supposed to provide valuable insight regarding
usefulness of focused screening program in T2DM as
effective therapies have evolved for HCV which may
prevent complications caused by HCV in this subgroup.
The objective of this study was to determine the pre-
valence of HCV in patients with T2DM and to elucidate
the presence of association between HCV and T2DM by
comparing seropositivity rates in diabetic patients with a
control group comprising of healthy volunteer blood
donors from the same area. Data was also analyzed for
the presence of difference among various groups with
respect to various variables after dividing patients into
two groups on basis of HCV infection status.
Methods
Participants
The study was carried out on a sample of 3000 consecu-
tive persons with confirmed type 2 diabetes visiting Dia-
betes clinic at Nishtar Medical College Hospital, Multan
for follow up. Subjects were excluded if they had type 1
diabetes, were transplant recipients, emergency cases or
dialysis patients. A control group comprising of healthy
blood donors were taken from the same hospital who
visited the blood bank during the study period. Controls
were excluded from the study if they had diabetes. Ethi-
cal clearance for the study was obtained from the Ethics
Review Committee of hospital.
Sample Collection and Antibody Detection
Sample collection was carried out using sterile needle
and syringes which were transferred to the lab for analy-
sis. 3 ml of peripheral blood was obtained via venepunc-
ture for each subject. The blood was centrifuged and
sera were stored in dry clean sterile containers at -20C
prior to use. Serological analysis for the detection of
anti-HCV antibodies was carried out using Accurate
rapid immunochromatographic kits. Positive cases were
later confirmed by using third generation ELISA kit
(Labkit Chemelex, S.A., Barcelona, Spain) for qualitative
detection of anti-HCV antibodies.
Data Collection
After explaining the purpose of the study, written
informed consent was taken from the participants before
collecting data and taking samples. Data was collected
using a structured questionnaire containing questions
related to demographic and clinical characteristics of
patients.
Statistical Analysis
Data analysis was carried out using SPSS software.
Descriptive analysis was performed and the results were
expressed as means and percentages. Odds ratio (OR)
and their respective 95% confidence intervals (CI) were
calculated. Pearson chi-square test was used to
Jadoon et al. Virology Journal 2010, 7:304
http://www.virologyj.com/content/7/1/304
Page 2 of 6determine the difference among various categories with
respect to HCV seropositivity. A p value of <0.05 was
considered statistically significant.
Results
The study population comprised of 3000 patients with
diabetes and 10,000 controls recruited from the blood
bank. The mean age of diabetes patients was 48.19 ±
10.32 years and the mean duration of diabetes was 6.26
± 5.50 years. Majority of patients with T2DM were
female (55.7%) and in the age group 36-45 years
(34.7%). Most of the cases were married (94.8%) and
were from urban localities (71.8%). Family history of dia-
betes was present in only 19.5% of the participants with
majority of participants having poor glycemic control
(75.2%). Description of the study group is outlined in
table 1. The controls were predominantly males with a
median age of 27 years.
Screening for the presence of anti-HCV antibody was
positive in 906 (6.97%) patients in the entire study
group. The seroprevalance was 13.7% in patients with
T2DM as compared to the control group in whom
prevalence rate was 4.9%. Analysis revealed that diabetic
patients had significantly higher prevalence of HCV
infection as compared to the control group (OR = 3.03,
95%CI = 2.64-3.48, p = 0.001).
The distribution of HCV infection in diabetic patients
was then studied with respect to age, gender, marital
status, locality, family history of diabetes, duration of
diabetes and glycemic control. The results of analysis
are presented in table 2. Patients older than 55 years,
male patients, having duration of diabetes more than 11
years and the ones with good glycemic control were
seen to be have significantly higher seropositive rates of
HCV infection as compared to other groups in respec-
tive categories (p < 0.05). It was found that categories
with respect to marital status, locality and family history
of diabetes recorded no significant difference in seropre-
valence among themselves (p > 0.05).
Discussion
In the present study, we found high prevalence of HCV
infection in patients with T2DM as compared to the
control group comprising of healthy volunteer blood
donors (13.7% vs. 4.9%). The results of our study are in
agreement with those of some studies conducted earlier
in other countries [7,11,13,14,25,27,28,31]. The findings
also agree with another study conducted earlier in the
country albeit with a small sample use and no control
group who recorded prevalence of 36% among diabetics
[31]. This is thus the first study to the best of our
knowledge in the country which employs a large sample
comprising of consecutive patients compared with con-
trol group of consecutive blood donors. Furthermore,
the prevalence of 4.9% in blood donors in our study is
comparable to earlier studies from Pakistan [22]. The
study thus establishes presence of T2DM as a risk factor
for HCV infection in this region.
It was observed that older patients were more likely to
have HCV infection as compared to those in the
younger age groups [11,20,21,25,28]. The high seroposi-
tivity recorded in older group may be because of more
parenteral exposures as compared to younger people
and thus greater chances of transmission of infection.
Analysis of HCV seropositivity rates with respect to
gender revealed that males had higher HCV infection
rate of 15.3% as compared to females in whom preva-
l e n c er a t eo f1 2 . 4 %w a sf o u n d .T h i sa g r e e sw i t ht h e
work of Caronia et al. who observed that male diabetics
are more likely to contact HCV infections as compared
to females [32]. A significant difference was also
observed among patients with T2DM with respect to
duration of diabetes. In relation to glycemic control, it
was seen that patients with good glycemic control were
significantly more at risk of having HCV infection as
compared to those with poor glycemic control. This
Table 1 Description of the study group (n = 3000)
Diabetes Group
Variables N %
Age
≤35 Years 360 12.0
36-45 Years 1042 34.7
46-55 Years 933 31.1
>55 Years 665 22.2
Gender
Male 1330 44.3
Female 1670 55.7
Marital Status
Unarried 157 5.2
Married 2843 94.8
Locality
Urban 2154 71.8
Rural 846 28.2
Duration of Diabetes
1-5 Years 1653 55.1
6-10 Years 855 28.5
>11 Years 492 16.4
Family History of Diabetes
Yes 2414 80.5
No 586 19.5
Glycemic Control
Good 744 24.8
Bad 2256 75.2
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rants further investigation.
We did not observed any difference in the HCV distri-
bution in study population with respect to marital sta-
tus, place of residence of participants and family history
of diabetes. Our findings regarding family history of dia-
betes differ from those of an earlier study from Nigeria
[25]. The difference may be explained by the difference
in proportion of patients with family history of diabetes
(19.5% vs. 8.3%) and the difference in epidemiology of
diabetes and HCV between the two countries.
The study has certain strength as well as same limita-
tions. The study has relatively large sample size as com-
pared to most of earlier studies and enrolled
consecutive patients thus reducing recruitment bias and
increasing generalizability of findings to a greater popu-
lation. Secondly, the study used a control group for
comparison of findings with the diabetic group. The
control group was recruited from the same area as the
cases. Furthermore, the study is first of its kind from
the region and the first large scale controlled study from
ac o u n t r yw i t hah i g hn u m b e ro f patients with diabetes
in which coinfection with HCV can have important
implications. The study also has some limitations. We
do not have the data on some of the potential con-
founding factors like exposure to risk factors such as
blood transfusion. Moreover, we were not able to con-
firm the results of screening by using polymerase chain
reaction to detect HCV RNA due to financial and tech-
nical constraints. Also we did not study liver enzyme
levels in diabetic patients and controls.
The study has some important implications. The
increased risk of HCV infection in patients with T2DM
warrants screening diabetes person for HCV. Secondly,
the study adds to the limited data on the subject avail-
able in this region and will help in increasing awareness
regarding association of HCV and diabetes which will
help in reducing morbidity and cost associated with this
comorbidity in the long run. Prospective, multicentre
studies are needed to establish temporal association,
Table 2 Distribution of HCV pattern in diabetic patients (n = 3000)
HCV Status
Variables Positive
n(%)
Negative
n(%)
OR 95% CI P value
Age .001
≤35 Years 38 (10.6%) 322 (89.4%) - -
36-45 Years 103 (9.9%) 939 (90.1%) 0.93 0.63 - 1.38
46-55 Years 101 (10.8%) 832 (89.2%) 1.03 0.69 - 1.53
>55 Years 168 (25.3%) 497 (74.7%) 2.86 1.96 - 4.18
Gender .023
Male 203 (15.3%) 1127 (84.7%) - -
Female 207 (12.4%) 1463 (87.6%) 0.79 0.64 - 0.97
Marital Status .075
Unmarried 14 (8.9%) 143 (91.1%) - -
Married 396 (13.9%) 2447 (86.1%) 1.66 0.95 - 2.89
Locality .184
Urban 323 (15.0%) 1831 (85.9%) - -
Rural 109 (12.9%) 737 (87.1%) 0.84 0.66 - 1.06
Duration of Diabetes .040
1-5 Years 231 (14.0%) 1422 (86.0%) - -
6-10 Years 107 (12.5%) 748 (87.5%) 0.88 0.69 - 1.13
>11 Years 90 (18.3%) 402 (81.7%) 1.38 1.05 - 1.80
Family History of Diabetes .143
Yes 319 (13.2%) 2095 (86.8%) - -
No 91 (15.5%) 495 (84.5%) 1.21 0.94 - 1.55
Glycemic Control .001
Good 139 (18.7%) 605 (81.3%) - -
Bad 268 (11.9%) 1988 (88.1%) 0.59 0.47 - 0.73
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mechanism and determination of other aspects of the
relationships.
Conclusions
In conclusion, there is a significant association between
Hepatitis C virus infection and type 2 diabetes in the
region according to the findings of the present study.
However, it remains to be seen whether diabetes is a
risk factor for the HCV infection or vice versa. It is
also evident that certain factors including older age,
male gender, longer duration of diabetes and good gly-
cemic control significantlyi n c r e a s et h er i s ko fh a v i n g
HCV infection which warrants special attention to
patients with these risk factors. It is important that
health care workers pay attention to prompt diagnosis
and management of the condition in affected diabetic
patients. Further investigation into the association of
the two conditions is needed and may elucidate the
temporal relationship and improved management
strategies.
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